Edited by: Michael Wechsler
Modulation of allergen-induced bronchoconstriction by fluticasone furoate and vilanterol alone or in combination
Article first published online: 7 AUG 2013
© 2013 The Authors. Allergy published by John Wiley & Sons Ltd
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Volume 68, Issue 9, pages 1136–1142, September 2013
How to Cite
Modulation of allergen-induced bronchoconstriction by fluticasone furoate and vilanterol alone or in combination. Allergy 2013; 68: 1136–1142., , , , , , .
- Issue published online: 18 SEP 2013
- Article first published online: 7 AUG 2013
- Manuscript Accepted: 9 MAY 2013
- 13Dose-related efficacy of vilanterol trifenatate (VI), a long-acting beta2 agonist (LABA) with inherent 24-hour activity, in patients with persistent asthma. Eur Respir J 2012;40:570–579., , , , , et al.
- 15Global initiative for asthma: Global strategy for asthma management and prevention. Updated 2011. Available at: http://www.ginasthma.org/. Last Accessed 29 July 2012.
- 21Fluticasone furoate, a novel enhanced-affinity inhaled corticosteroid (ICS), with sustained glucocorticoid receptor nuclear translocation. Am J Respir Crit Care Med 2010;181:A5409., , , , .
- 22Fluticasone furoate, a novel enhanced-affinity inhaled corticosteroid (ICS), has more potent anti-inflammatory effects than fluticasone propionate in peripheral blood mononuclear cells from asthma and COPD patients. Am J Respir Crit Care Med 2010;181:A4454., , , , , et al.